Scarica l'app Stockscreener
12.12
11.29%
1.23
Dopo l'orario di chiusura:
12.25
0.13
+1.07%
Precedente Chiudi:
$10.89
Aprire:
$12
Volume 24 ore:
472.12K
Relative Volume:
2.23
Capitalizzazione di mercato:
$1.61B
Reddito:
$7.50M
Utile/perdita netta:
$-81.89M
Rapporto P/E:
0.2286
EPS:
53.0176
Flusso di cassa netto:
$-63.58M
1 W Prestazione:
+15.98%
1M Prestazione:
+13.91%
6M Prestazione:
-38.79%
1 anno Prestazione:
+78.76%
Intervallo 1D:
$11.72
$12.50
Intervallo di 1 settimana:
$10.32
$12.50
Portata 52W:
$5.78
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
Nome
Mesoblast Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MESO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
12.12 | 1.61B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-23 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-24 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-23 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Downgrade | Maxim Group | Buy → Hold |
| 2023-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Iniziato | William Blair | Outperform |
| 2022-12-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-06 | Iniziato | Piper Sandler | Overweight |
| 2021-04-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-12-22 | Downgrade | Maxim Group | Buy → Hold |
| 2020-12-04 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2020-05-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-31 | Ripresa | H.C. Wainwright | Buy |
| 2018-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-08-31 | Iniziato | Oppenheimer | Outperform |
| 2017-06-08 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Mesoblast Ltd Adr Borsa (MESO) Ultime notizie
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewswire Inc.
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.43% - Investing.com
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart
ASX dives as Trump tests COVID positive - The Australian
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal - Yahoo Finance
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - streetwisereports.com
6 ASX BioTechs Trading on the NASDAQ - TheBull.com.au
Mesoblast Ltd Adr Azioni (MESO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):